SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer Therapeutics, Imaging Technologies, Interventional Devices, Diagnostics, and Prognostics Toward Commercialization (R44) | Apply Online

Opportunity Summary:

The SBIR Phase IIB Bridge Awards FOA (RFA-CA-11-002) is a National Institutes of Health opportunity designed to help small business concerns move cancer-related SBIR Phase II projects from late-stage development into commercialization. It specifically targets technologies that have already been supported through an NIH SBIR Phase II award and now need additional funding to reach the market, especially for the expensive, high-risk steps that often sit between a successful Phase II outcome and a commercially viable product.

The scope is limited to cancer-focused projects in three broad categories: cancer therapeutics; cancer imaging technologies, interventional devices, and in vivo diagnostics; and in vitro or ex vivo cancer diagnostics and prognostics. In practice, that means the program is meant for product-driven efforts such as drug candidates and biologics aimed at cancer, imaging agents or platforms used to detect or monitor tumors, interventional tools used in cancer care, and laboratory-based diagnostic or prognostic tests that can be performed on patient samples outside the body. Projects can be at either the preclinical or clinical stage, and while clinical trials are allowed if they make sense for the technology and development plan, they are not mandatory.

A core feature of this Bridge Award is the strong emphasis on commercialization readiness and external market validation. The FOA is structured to encourage partnerships between NIH-funded small businesses and third-party investors or strategic partners (for example, venture investors, corporate partners, or other non-federal backers) who can help finance and de-risk the path to market. Applicants are required to submit a Commercialization Plan, consistent with SBIR application requirements, and that plan needs to clearly explain the commercial strategy and provide specific detail on independent third-party funding that has already been secured or is expected during the Bridge Award period. The program sets a clear expectation that the amount of independent third-party support will equal or exceed the amount of NCI funds requested across the Phase IIB Bridge project period, effectively making this a co-funded push toward commercialization rather than a stand-alone federal award.

From a funding and administrative standpoint, this is a discretionary grant opportunity under the SBIR mechanism (R44). The estimated total funding available is $10,000,000, with an award ceiling of $1,000,000 per award, and there is no cost sharing or matching requirement in the traditional sense. However, the practical expectation of third-party investor participation functions like a commercialization-focused matching dynamic, since applicants are expected to bring in outside capital at least comparable to the requested federal amount. Eligibility is limited to small businesses. The FOA was posted on February 3, 2011, with an application closing date of April 7, 2011, and it was archived on May 8, 2011. The opportunity is associated with CFDA numbers 93.394 (Cancer Detection and Diagnosis Research) and 93.395 (Cancer Treatment Research).

Overall, the program is best understood as a bridge from SBIR Phase II into the market: it funds the next set of critical development activities that can include advanced preclinical validation, product finalization and engineering, regulatory preparation, manufacturing scale-up considerations, and potentially clinical testing, while simultaneously pushing companies to demonstrate investor or strategic partner commitment. The intended outcome is to accelerate real-world commercialization of promising cancer therapeutics, devices, imaging tools, and diagnostics that are already beyond early feasibility and are ready for the final development sprint toward widespread use.

Browse more opportunities from the same agency: National Institutes of Health

Browse more opportunities from the same category: Education Health

Next opportunity: FY 2011 SaDIP Grant Opportunity Announcement

Previous opportunity: 2011 NIDA Translational Avant Garde Award for Medication Development for Diseases of Addiction (DP1)

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for RFA CA 11 002

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (RFA CA 11 002) also looked into and applied for these:

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "RFA CA 11 002", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.